Emerging from the bustling tech scene of France, Gleamer, an AI healthcare start-up, has successfully secured €27 million ($29.5 million) in a Series B funding round. Now five years into its journey, Gleamer continues to redefine the landscape of radiology with its cutting-edge AI software designed to streamline the diagnosis of bone trauma lesions and other similar conditions.
Initiated in 2017, Gleamer has been making waves with its flagship product, BoneView, a software solution marketed as the “AI companion for bone trauma x-rays”. The ingenious system illuminates areas in radiology scans that may display abnormalities, skillfully addressing potential human error by highlighting anomalies often overlooked by the unaided eye. Additionally, the company has rolled out ChestView, an AI tool specifically engineered for the detection of pulmonary pathologies.
In a testament to the company’s innovation and commitment to high-quality healthcare solutions, all of Gleamer’s products have successfully attained European certification, with BoneView also receiving FDA clearance in the U.S. The technology is rapidly gaining traction, boasting approximately 6,500 users spread over 650 institutions across 24 countries.
The healthcare industry is facing a growing demand for efficient and reliable medical imaging services, fueled by factors such as increasing rates of chronic diseases, funding constraints in healthcare systems, and ageing demographics. Gleamer is at the forefront of meeting these needs, capitalizing on this surge by offering advanced, AI-powered solutions to the medical community.
Recently, the U.K. government emphasized the importance of AI in healthcare by unveiling a new £21 million fund aimed at incorporating more AI technology into the National Health Service (NHS). This initiative particularly targets the enhancement of medical imaging capabilities. Simultaneously, several start-ups worldwide are securing substantial VC funding to innovate and enhance the field of radiology. Developments range from portable x-ray machines to AI-driven “decision support” software and private medical imaging marketplaces.
Since its inception, Gleamer has raised an impressive total of €36 million. The latest round of funding will fuel the company’s ambitious growth plans, which include broadening its product range to incorporate CT scans and mammography. Furthermore, Gleamer intends to expand its talented team within Europe and the U.S, reinforcing its global footprint.
The Series B funding round attracted an array of high-profile investors, co-led by Supernova Invest and Heal Capital. Others who participated in this round include XAnge, Elaia, Bpifrance, F3A, MACSF, Crista Galli Ventures, UI Investissement, along with several European radiologists. With such robust backing and a powerful vision, Gleamer is poised to continue its trailblazing journey, revolutionizing the world of radiology through AI.
